Hepatx was founded by Eric Schuur in 2015.

Who are Hepatx's investors?

Hepatx's investors include iSelect Fund, Sand Hill Angels, Y Combinator.

Where is Hepatx headquartered?

Hepatx is headquartered in San Francisco, US.

Hepatx

San Francisco, US · Founded 2015 · 4 employees · 3 known investors

Find your way into Hepatx

1,075 people in our graph share verified history with the Hepatx team — schools, employers, funds. One of them is your warm intro.

Paul Kwanunlockedknows Eric Schuur · together at Stanford University (overlapped)

×5knows the team · via Stanford University

×4knows the team · via Y Combinator

knows the team · via UCLA

knows the team · via StartX

HepaTx develops stem cell-based hepatocyte therapies for liver disease treatment as an alternative to organ transplantation. The company targets niche liver disease indications including alpha-1 antitrypsin deficiency, phenylketonuria, and non-alcoholic steatohepatitis.

Also known as Hepatx Corporation

Biotech Healthtech Medical DevicesUnited States of AmericaAmerica / CanadaPartly Remote

Founders & leadership· Y Combinator alumni (S18)

Hepatx was founded in 2015 by Eric Schuur.

Eric Schuur in 𝕏Chief Executive Officer, Co-founderWith over 25 years in biopharma and medical devices, he has held leadership roles in regenerative medicine and cell therapy development, including work on oncolytic virus development at Calydon and clinical program leadership at Asthmatx, and has authored numerous peer-reviewed publications and patent applications.

Investors · 3

iSelect FundSt. Louis · $250K – $2M

Sand Hill AngelsMenlo Park · $50K – $2M

Y CombinatorSan Francisco · $500K

Competitors · 2

by search overlap

TheratomeBio5 shared keywordsTheratome Bio is a regenerative medicine company using artificial intelligence to develop secretome-based therapeutics that address tissue repair and disease. The company focuses on organ transplant preservation and dry eye disease treatments.

Haya Therapeutics5 shared keywordsHAYA Therapeutics develops precision RNA medicines that target long non-coding RNAs (lncRNAs) in the regulatory genome to reprogram disease at the level of cell state, with a lead program in cardiac fibrosis and work in obesity and metabolic disease. The biotech company builds a regulatory genome platform to discover tissue- and cell-specific lncRNA targets and turn them into oligonucleotide-based therapies.

Companies competing with Hepatx for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Institutes of Health (NIH)National Institutes of Health	Phase I	2019	$225K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2017	$149.7K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Hepatx Corporation - BIO Investor Forum 2024bif.bio.org

Frequently asked questions

What does Hepatx do?: HepaTx develops stem cell-based hepatocyte therapies for liver disease treatment as an alternative to organ transplantation. The company targets niche liver disease indications including alpha-1 antitrypsin deficiency, phenylketonuria, and non-alcoholic steatohepatitis.
Who founded Hepatx?: Hepatx was founded by Eric Schuur in 2015.
Who are Hepatx's investors?: Hepatx's investors include iSelect Fund, Sand Hill Angels, Y Combinator.
Where is Hepatx headquartered?: Hepatx is headquartered in San Francisco, US.